High quality proteomics.
Unrivaled throughput.
One protein biomarker platform with endless possibilities – understand real-time human biology.
See our ground-breaking PEA technology in action.
Flexibility without compromise
Introducing Olink® Flex
Olink’s highly flexible made-to-order product, Olink® Flex, enables you to select and combine targets for up to 21 human proteins in one biomarker panel
From broad discovery to targeted studies, in every research setting, our PEA technology is the proteomics solution for fast, accurate, and actionable results.
Put protein biomarkers at the heart of your strategies for faster development of safe, effective therapies for the precision medicine era.
With the right set-up, you can add our game-changing proteomics platforms to your technology suite to run Olink kits in-house, or even become a trained Olink external service provider.
Accelerate your approach to proteomics.
Olink® Insight
See data in new ways, collaborate faster and easier with peers, and access exclusive data sets.
How can we help you?
Accelerating proteomics together, with you
World-class technology, products and services are important, but we don’t think that’s enough. We are also passionate about collaboration and transparency, supporting and working with our customers to help them better understand real-time human biology to the benefit of all.
Proven technology
Hundreds of millions of protein data points generated an extensive body of peer-reviewed publications in just a few short years
Expertise
Our dedicated, knowledgeable teams and Olink Insights tools will support you all the way from study design through to data analysis and beyond
Transparency
∼ 3000 thoroughly validated, high quality proteins assays – all validation processes and data transparently shared with you
Our Community
The “Olink community” isn’t just a phrase, we support scientists and their collaborative initiatives whenever they need us
Heart to heart – Faiez Zannad in his own words
Customer stories
Professor Faiez Zannad, one of the world’s foremost researchers in the area of heart failure, talks about his work, and the importance of protein biomarkers in his field
Strategies for design of protein biomarker studies
White papers
This white paper describes important aspects of study design to consider when planning your future research.
Ensuring quality with flexibility- Olink® Flex validation & verification
White papers
This white paper transparently presents some of the results from our verification and validation tests carried out during the development of Olink Flex.
Longitudinal COVID-19 proteomics study from MGH
COVID-19, Customer stories, Disease areas
Olink is immensely proud of our contribution to one of the largest longitudinal COVID-19 studies together with the prestigious Massachusetts General Hospital (MGH).
A rare but severe complication in children with COVID-19
COVID-19, Customer stories, Disease areas
A study by Petter Brodin's group at the Karolinska Institute sheds new light on Inflammatory Syndrome in Children (MIS-C). The results were published in Cell.
Protein biomarkers of COVID-19 pathophysiology (Radboud UMC)
COVID-19, Customer stories, Disease areas
A team from the Netherlands used targeted proteomics to find inflammatory and other biomarkers that characterize COVID-19 and the severity of the disease.
Immune system development in children – Petter Brodin
Customer stories, Understanding human biology
Petter Brodin talks about his landmark study (Olin et al, 2018), published in Cell, "Stereotypic immune system development in newborn children"
SCALLOP publication in Nature Metabolism
Customer stories, Drug discovery and development
SCALLOP consortium study in Nature Metabolism identifies protein quantitative trait loci (pQTL) for 90 cardiovascular proteins in over 30,000 individuals.
Systems-level immunomonitoring of severe COVID-19
COVID-19, Customer stories, Disease areas
A longitudinal, systems-level approach characterizes cellular and protein immune responses in severe COVID-19, and during the recovery phase following severe disease.
View from the inside – SCALLOP pQTL CVD I study
Customer stories, Drug discovery and development
SCALLOP founder, Anders Mälarstig, talks about the consortium’s first major combined study, which was recently made available on bioRxiv
News
2947
Biomarker assays
~881 million
Protein data points generated
1281
Publications listed on website